HLB Therapeutics Co.,Ltd.
115450
Rang in aandelen
#18346
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Aandeelprijs
$2.07
Marktkapitalisatie
$194.92M
Verandering (1 dag)
10.37%
Verandering (1 jaar)
1.05%
Land
KR
Handel HLB Therapeutics Co.,Ltd. (115450)
Categorie
Healthcare
P/S-ratio voor HLB Therapeutics Co.,Ltd. (115450)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van HLB Therapeutics Co.,Ltd. is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor HLB Therapeutics Co.,Ltd. van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| Niet genoeg gegevens voor de verstrekte datums. | ||
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
